adagrasib
mirati
['lcsm,(-blcsm)', 'sclc', 'nsclc', 'adagrasib']
adagrasib targeting kras g12c mutation in mnsclc continues to show promise in ph 2 trial. 1-year overall survival 51%; side effect profile manageable (though this is relative); &amp; potential effect on controlling brain mets. another 2l option? #lcsm #asco22 
LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer.